Nevertheless, our demonstration of increased PD-1+ T cells in the aging mouse prostate may still be useful information given the recent interest in developing immunotherapies targeting the PD-1/PD-L1 axis in prostate cancer [55–57]. This evidence concerns the gene PDCD1 and Familial prostate cancer.